Evidence map›Paper›PMID 34446966›Full record

ArticleIndian journal of dermatology

Intravenous Immunoglobulin: Revisited - My Experience.

Sanjeev S Vaishampayan, Surendra Singh Bhati, Radha R Lachhiramani, Shivank Shrivastava, Prateek Jain, Ajay Singh Raghuwanshi

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sanjeev S VaishampayanDepartment of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
Surendra Singh BhatiDepartment of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
Radha R LachhiramaniDepartment of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
Shivank ShrivastavaDepartment of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
Prateek JainDepartment of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
Ajay Singh RaghuwanshiDepartment of Dermatology, Index Medical College, Indore, Madhya Pradesh, India.
Index Medical College, Hospital & Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMany a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises.

methodOver the last 15 years of my practice I have used IVIg in various severe or recalcitrant diseases (including TEN, autoimmune blistering disease,connective tissue disorders , chronic urticaria etc) which were either unresponsive to conventional modality of therapy or primary therapy could not be given because of co-morbidities.

resultIVIg a sterile, highly purified preparation containing more than 95% unmodified IgG,was first approved by FDA in 1981 for 6 diseases. As mentioned above in many circumstances we reached a situation when either conventional primary therapy was contraindicated or patients were not responding. IVIg came to our rescue in large number of conditions to tide over the crisis and also created the environment leading to conventional therapy becoming effective. Very few minor side effects like low grade fever and myalgia were observed in very few cases. No serious or severe side effects were seen, however , one has to be prepared for anaphylactic reaction which is a theoretical possibility.

conclusionIt can be said that IVIg though not a magic drug, is a very effective tool available in the armamentarium of Dermatologists to treat plethora of chronic and intractable dermatoses.

Indexed as

Chronic dermatosesindicationsintravenous immunoglobulin-revisited

Identifiers

PMID34446966
PMCPMC8375533
OpenAlexW3186324501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.